Kraig Biocraft Laboratories, Inc. is an emerging biotech company with a very strong
intellectual property portfolio relating to genetic modification of silkworms to
produce spider silk and other specialized proteins. The company's technical team
is making use of some of the most advanced insect-related genetic engineering techniques
known including piggyBac transposition to create a germline stable transgenic silkworm
capable of transferring the inserted spider silk genetic coding to future generations.
A significant market valued in the tens of billions of dollars per year already
exists for highly resilient technical fibers, with DuPont’s Kevlar dominating the
market. Spider silk demonstrates similar strength characteristics to many man-made
fibers in this category, but significantly exceeds all known fibers relative to
its ability to absorb energy prior to breakage, making it a potential “super fiber”
for a host of ballistic resistant, medical, fashion, and industrial applications.
Should this company achieve its goal of creating transgenic silkworms capable of
expressing significant amounts of spider silk proteins; we believe the technology
will likely immediately be worth at least several hundred million dollars. Further
refinement of the technology and initial acceptance by the technical textiles market
could potentially yield an overall value for this technology well in excess of $1
billion.
We believe success in the laboratory yielding the first transgenic silkworm capable
of producing spider silk would be a major scientific achievement and would also
likely yield significant coverage in the business and popular presses, and of course,
significant price appreciation of KBLB shares.
